Ind Swift Limited is a part of the 300 Mn USD Ind Swift Group with presence in both the
human formulations and bulk drugs. Our strength lies in the fact that we are a fully vertical integrated group as a result of being present in all segments of the pharma chain namely, the Intermediates, API's and Finished formulations. We have the manufacturing and marketing capabilities for all the above related segments and have etched out a decent presence in both the national and international markets. The company is a leader in the API segment (both on
the domestic level and in the international markets) and after establishing its presence in the
semi regulated markets, has been working on consolidating its presence in the regulated markets in the formulation arena globally.
Our API plant is US FDA, TGA Australia approved and we have a number of DMF's to our
credit. The formulation plant is WHO GMP approved and has approvals from UK, MHRA and
TGA, Australia, MoH UAE apart from various other approvals across the globe. Our direct
presence in key international markets is through various routes e.g. by way of a wholly owned
subsidiary in the US, JV in Iran, companies in Dubai and China etc.

Core Sales Territory: Global Regulated Markets

Core Operation: Sales and Marketing Finished Dose Manufacture

Number of molecules sold: 130

Company's rating: